INTRODUCTION
The approval of sipuleucel-T (Provenge) [1] for patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer as well as the recent success and approvals of the checkpoint inhibitors ipilimumab (anti-CTLA-4, Yervoy, Bristol-Myers Squibb, Princeton, NJ) [2] , nivolumab (anti-PD1, Optivo, Bristol-Myers Squibb, Princeton, NJ) [3 && ] and atezolizumab (Tecentriq, Genentech, San Francisco, CA) [4 && ] has rekindled interest in an area that was largely dominated by immunologists but now is embraced by clinicians. Highly desirous is an off-the-shelf therapy that is easily exportable, is effective, and has an appropriate endpoint associated with a biologic effect. This has been exemplified by the checkpoint inhibitors. Yet despite the successes of these agents in solid tumors, it remains unclear why prostate cancer does not exhibit the same level of robustness seen in other malignancies. To date, several observations have been made to explain this, including the fact that prostate cancer is not a significantly mutated tumor compared with other solid tumors, increasing doses of vaccines do not correspond with increasing immunogenicity, and that high titers of antibodies against specific immunogens used in a vaccine do not correspond with changes in the biology of the disease leading to an antitumor effect. In addition, there was no potentiation of T-cell responses, and more importantly, immunologic signals were not immediate, leading to concerns by physican and patients alike as to whether or not other therapies should be initiated. Tumor-associated antigens (TAAs) have to be induced or enhanced, which takes time. So why does it take time to generate a response? In some, if not all instances, it may only be a subset of cells that express the most relevant TAAs. If such early tumor-initiating cells are being targeted preferentially, and many of their TAAs are not expressed on more differentiated tumor cells, one would not expect any immediate effects on existing tumor lesions. These cells may not be initially detectable as they may be harbored in privileged sites and therefore may only become after a few more proliferations of these soon-to-be terminally differentiated tumor cells.
UNDERSTANDING THE IMMUNOLOGIC MILIEU
There have been numerous studies attempting to interrogate the intraprostatic milieu and defining the immune environment. This has remained a challenge as the immunologic milieu is likely to change drastically over the transition of the disease from localized to metastatic state. Another challenge has been related to the influence of age on the immune system such that the de novo milieu seen may be affected by older age relative to younger patients where certain cell populations may be more robust. As seen in Table 1 , the benefits of early and direct biopsy of the prostate permit the evaluation of baseline assessment; changes in the structural and immunologic milieu can easily be evaluated with established panels of immune cell surface markers. These have included looking at T-lymphocyte subsets and their respective ratios, natural killer cells (NK), as well as a variety of novel markers such as cytotoxic T lymphocyte antigen-4 (CTLA-4), Inducible T-cell COStimulator (ICOS), OX-40 (CD 134), programmed cell death protein 1 (PD-1), and programmed cell death 1 ligand (PD-L1). The earliest exploration into the immune network has focused on NK cells in a variety of cancers [5] [6] [7] ; observations regarding the infiltration of immune cells around cancerous foci have been noted by many. The mechanism of how NK cells work, their expression phenotypes and activation signals represent an immense body of work. NK cells have known active natural cytotoxicity receptors [NKp46 (natural cytotoxicity receptor), NKp30, NKp44, Natural Killer G2D, CD 94, and DNAX accessory molecule-1, CD226 along with inhibitory killer immunoglobulin-like receptors, CD94/NKG2A, and ILT2/CD85 (ILT2 also known as leukocyte Ig-like receptor 1, CD85j, and LILRB1)]. Arnon et al. [8] demonstrated that in prostate cancer the ligands for NKp30 and NKp46 were not found on normal tissue as seen in benign prostatic hyperplasia but were expressed on primary tumors. Gannon et al. [9] showed that the presence of NK cell infiltrate within the prostate cancer foci was associated with a lower risk of progression suggesting that these cells may have some protective function. Pasero et al. [10 ] examined the frequency, phenotype, and function of NK cells that infiltrate both normal and cancerous prostates, which represented for the first time a thorough analysis of NK cell phenotype and function in peripheral blood, normal, and prostate cancer
KEY POINTS
There continues to be interest in exploring the intratumoral/stromal milieu to further define intrinsic characteristics that may lead toward a better understanding of how intratumoral suppression can be alleviated to foster greater responses to immune therapies.
Combinatorial approaches with immune modulating agents and standard treatments such as radiation or chemotherapy may be beneficial.
The resistance of the prostate to ipilimumab may not be indicative of lack of future response to anti-PD-1 or PD L1 drugs.
Immune suppression plays a major role in diminishing the robustness of immune therapies.
Antiandrogen may play an important role in modulating immune responsiveness. tissues. The authors demonstrated that an unusual pattern of NK cells was seen, that is, a CD56 bright subset was increased within the prostate gland suggesting an immature but activated phenotype compared with peripheral blood. NK cell infiltrates within the prostate tissues were mainly CD56 Neural Adhesion Molecule-1 (NCAM-1) positive and demonstrated low or no ex-vivo cytotoxic potential. Interestingly, TGFb1 was highly secreted into the prostate environment and appeared to partly mediate the immunosuppressive effects of NK cells. What was unforeseen was that as cancer cells infiltrated the prostate microenvironment, the prostate environment became resistant to NK cell-mediated immunity. The authors concluded that there was a strong immunosuppressive environment within the prostate that can impair NK-cell function at several levels. These observations have provided new groundwork not only for understanding the immunologic milieu between normal and cancerous prostates but may provide a means for future in-vivo immunologic manipulations to restore NK function within the natural environment. Mention should also be made of inflammatory cytokines that may be useful in disease prevention and treatment. These include the TH 1 cytokines, IFNg and TNFa, and 'innate cytokines', such as IL-6, known to potentiate immune responses to tumor, whereas IL-1b, IL-8, and IL-10 may repress anticancer immunity. Bhavsar et al. [11] conducted an age-race matched case-control study (268 pairs) of incident prostate cancer from the CLUE-II trial. Plasma IFNg, IL-10, IL-12p70, IL-1b, IL-6, IL-8, and TNFa concentrations were measured using an ultrasensitive multiplex kit. The authors observed that those TH 1 cytokines as well as a higher level of IL-6 statistically could possibly be associated with a lower risk of prostate cancer, including aggressive disease. These data are of interest and are further supported by other studies [12] suggesting that there were variations in some immune response genes that may govern prostate cancer risk. The conclusions from these studies open concerns regarding whether there are specific immunologic profiles that may explain whether there is something within the normal prostate intraprostatic immune milieu that can protect against prostate cancer; whether the immune milieu in response to a prostate adenocarcinoma inhibits tumor growth and detectability, and/or performing such immune profiling studies will lead to developing a systemic immune signature profile that mediates the other modifiable factors on risk.
A study by McNeel, et al. [13] examined peripheral blood mononuclear cells from patients with prostate cancer and male controls without prostate cancer, respectively. The immunologic profile as defined by T-helper cell responses were assessed using antigen-specific proliferation in addition to measuring IFNg and IL-5 secretion in response to antigen stimulation using ELISA. Of the patients tested with prostate cancer, T-cell proliferative responses specific for PSA and prostatic acid phosphatase (PAP) were detected, with 6% of 80 patients having T-cell responses specific for PSA and 11% of patient for PAP. Those patients with T-cell responses for PSA seemed to be significantly associated with the presence of metastatic disease; responses for PAP were detected in any patient irrespective of disease stage. T-helper cells that produced IFNg were specific for PSA and PAP only in prostate cancer patients. Although these responses appear to have some relationship to disease burden, nevertheless, the relative percentages of these subpopulations do not seem to correlate with changes in disease biology.
Other attempts to identify immune cells that may be reflective of changes in situ or systemically have focused on myeloid-derived suppressor cells (MDSCs). They are believed to play a role in immune suppression and the subsequent failure of T cells to generate an antitumor response either via a single or dual mechanism of direct T-cell inhibition or in combination with induction of T regulatory cells (Tregs). A study by Idorn et al. [14] investigated the frequency and function of immune suppressive cell subsets using peripheral blood of patients with prostate cancer and healthy donors. There was a significant increase in circulating CD14(þ) histocompatibility leukocyte antigen-DR(low/neg) monocytic MDSCs as well as Tregs in patients with prostate cancer compared with normal male donors.
Interestingly, there appears to be a positive correlation between the MDSC frequencies and Treg levels. An in-vitro proliferation assay with autologous T cells confirmed some measure of MDSCmediated T-cell suppression. There was a suggestion that a difference in median overall survival existed between patients with high vs. low MDSC frequencies. These observations were in keeping with observations in other diseases [15] .
Davidsson, et al. [16] , explored the associated role of Tregs in counteracting tumor rejection via suppressive functions on the anti-immune response. Using a nested case-control study in men who had undergone transurethral resection of the prostate and who found to have incidental prostate cancer vs. who died of their disease, pathology specimens revealed infiltration of both T helper and cytotoxic cells with the majority of the Tregs being CD4. Neither helper T cells nor T cytotoxic cells were associated with a lethal prostate cancer. However, what was unexpected was a near two-fold increased risk of lethal prostate cancer when comparing the highest with the lower quartile of CD4þ Treg cells. The authors concluded that men with greater numbers of CD4þ Tregs within the prostate milieu had an increased risk of dying of prostate cancer and that the identification of this cell population could be a predictor of clinically important disease at diagnosis. The authors concluded that mechanistically prostate cancer may result from some post atrophic hyperplasia. This would be in the setting of severe chronic insult as seen with by infiltration of inflammatory cells. A shift could be seen in the CD4/CD8 ratio or an inflammation-independent tumor-induced increase in the CD4 Treg population. They pointed out that this may explain prior observations as to why tumor-infiltrating lymphocytes did not show any specific T-lymphocyte subsets and may be responsible for the discrepancies therein. These results may be further supported by observations that Tregs that infiltrate the tumor may be because of the ability of tumor cells or macrophages within the tumor area to secrete chemokines, that is, C-C motif chemokine ligand 22 (CCL22), which has some avidity for the Treg receptor C-C motif chemokine receptor 4 (CCR4) [17] . In addition, cytokines that are secreted by the prostate cancer, that is, TGFg can upregulate FOXP3 transcription factor and induce expansion of the Treg population [18] .
CHANGING THE INTRATUMORAL MILIEU: ENHANCING INHERENT IMMUNOGENICITY
There have been multiple mechanisms by which prostate cancer cells can be rendered more susceptible to therapies. Although cytotoxic agents do so by providing some measure of cell killing, radiation has played an important role in potentially upregulating cell surface molecules that are involved in immune recognition [19 && ]. A recent study by Gameiro et al. [20 & ], treated cell lines derived from a variety of solid tumors with proton radiation and examined its effects on the viability and induction of immunogenic modulation by tumor cells. Proton and photon radiation was shown to upregulate histocompatibility leukocyte antigen, intracellular adhesion molecule 1 as well as antigens, carcinoembryonic antigen and mucin. T cell-mediated killing of tumor cells was increased via radiation-mediated calreticulin cell surface expression. Calreticulin (along with ERp57) acts to chaperone the major histocompatibility complex (MHC) class I protein; this in part prepares the MHC class I for binding a tumor antigen for its ultimate presentation on the cell surface. These observations confirming the role of radiation in inducing antigen upregulation was particularly true in prostate and breast cancer cells following exposure to photon and proton radiation. Interestingly, cancer stem cells also upregulated calreticulin after radiation. This was observed in the androgen positive lymph node derived human prostate cancer cell line such that exposure to proton radiation significantly increased cell surface expression of calreticulin in stem-like compared with nonstem-like populations. These data confirm the authors' prior work using photon beam radiation with docetaxel that showed increased tumor sensitivity to cytotoxic T-cell damage [19 && ]. The enhanced T-cell recognition and cytotoxicity by either photon radiation or chemotherapy could be abolished by blocking calreticulin-T cell interactions.
Additional immune modulation of the tumor microenvironment has been observed with the use of androgen deprivation therapy. Preclinical work by Hodges' group [21 && ] looked at the role of enzalutamide, an androgen-receptor (AR) antagonist that prevents the translocation of AR into the nucleus as an immune modulator. Using the transgenic adenocarcinoma of the mouse prostate-C2 model of prostate cancer (TRAMP), they were able to show that there was enhanced cell surface expression of Fas (Apo-1 or CD95), and MHC class I resulting in enhanced sensitivity to in-vitro immune-mediated lysis. Additional studies were built on these observations showing that a combination of a vaccine targeting a transcription factor along with enzalutamide could increase antigen-specific CD4 T-cell proliferation in mice compared with those that were untreated or given enzalutamide alone. There was an increase in antigen-specific CD8 T-cell cytokine production as well as an increase in responses against nonvaccine-induced antigens via CD8 T cells, the latter suggestive of antigen cascade. The authors concluded from their studies that those prostate cancer cell lines that expressed AR appeared to be more sensitive to T cell-mediated lysis compared with those cell lines that lacked AR, that is, PC-3 cells [22 && ]. These studies provide further insight into how the immunologic milieu may be better manipulated to provide an antitumor response to other therapies and may provide data for how androgen deprivation therapy could be used to change the intratumoral milieu to facilitate the use of a therapeutic vaccine or other therapies.
THE IMMUNOLOGIC PARADOX
Despite efforts to explain how the tumor microenvironment generates suppressive immune cells that may impact on prostate cancer biology, it is still unclear as to how even chemical castration modulates the immune environment. Anecdotal studies speculate on how castration may affect the tumor microenvironment as well as the overall systemic immune 'ecosystem.' The current use of sipuleucel-T suggests that CD54 þ cells are induced over time by the costimulation of peripheral blood mononuclear cells with the PAP-GM-CSF fusion protein [23] . The mechanism of induction may be linked to antigen spreading as speculated by many. However, while there is an overall survival benefit, there does not appear to be a significant antitumor effect. This remains somewhat of a mystery as the mechanism by which tumor cells appear to resist the effects of cellular induction by vaccine still remains unclear. Similarly, the checkpoint inhibitors have taken the immunology and oncology communities by storm providing long-term survival benefit in addition to durable antitumor responses. Despite anti-CTLA-4 providing benefit in melanoma [2] , anti-PD-1 (nivolumab) [3 && ] in melanoma, renal, and nonsmall cell-lung cancer, and now anti-PDL1 (atezolizumab) in urothelial cancer [4 && ], prostate cancer appears to be minimally responsive to this treatment although there have been rare long-term durable remissions [24, 25] . These patients have been evaluated but there are no data available to explain their success. Many theories abound to explain the lack of responsiveness, including possible polymorphisms in CTLA-4 or mutational status of the tumor [26] but the reason for its lack of response still remains unclear. Efforts are underway to further identify features that may indicate which patient may benefit from these therapies.
CONCLUSION
We have made considerable progress in understanding the intratumoral milieu, from dissecting immune cell populations to profiling these cells and defining the T-cell repertoire that might make them different than other cancers. Although, we are still lacking the success that is seen in other solid tumors, there is a strong likelihood that we will find the mechanism responsible for the resistance of this malignancy to immune therapies. It is clear that combinatorial approaches with some form of immune modulation along with chemotherapy or hormonal therapy will be of benefit but therein, the challenges still remain.
